Personalised mRNA vaccines have shown positive results as pancreatic cancer treatment, a phase 1 clinical trial found. Scientists say half of the participants responded to a trial vaccine, producing T cells that targeted their tumours, which means their life span could increase significantly. In more than 90% of cases, pancreatic cancer is diagnosed when it reaches the last stage.